Immuneering's Atebimetinib Shows Enhanced Efficacy in RAS Mutant Tumors
Event summary
- Immuneering will present preclinical data at SITC 2026 showing atebimetinib enhances PD-1 checkpoint blockade in RAS mutant tumors.
- Poster presentation scheduled for November 6, 2026, in Phoenix, AZ.
- Findings support plans for a Phase 2 study of atebimetinib in combination with PD-1 blockade in lung cancer patients.
- Atebimetinib is a Deep Cyclic Inhibitor of MEK, designed to improve survival across multiple cancer indications.
The big picture
Immuneering's data suggests a potential breakthrough in treating RAS mutant tumors, a historically challenging subset of cancers. The focus on combination therapy aligns with broader industry trends toward multi-targeted approaches in oncology. Success here could position Immuneering as a key player in precision oncology, particularly if atebimetinib demonstrates durable responses in Phase 2.
What we're watching
- Clinical Translation
- Whether preclinical enhancement of PD-1 blockade will translate into clinical efficacy in lung cancer patients.
- Regulatory Pathway
- The pace at which Immuneering advances the Phase 2 study following SITC presentation.
- Competitive Positioning
- How Immuneering differentiates atebimetinib in the crowded MEK inhibitor space.
Related topics